Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Jasper Therapeutics Inc (JSPRW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: JSPRW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -45.14% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 3755 | Beta 2.24 | 52 Weeks Range 0.08 - 0.25 | Updated Date 03/29/2025 |
52 Weeks Range 0.08 - 0.25 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.52% | Return on Equity (TTM) -101.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9909493 |
Shares Outstanding - | Shares Floating 9909493 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Jasper Therapeutics Inc
Company Overview
History and Background
Jasper Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of conditioning agents for hematopoietic stem cell transplantation and gene therapy. Founded in 2018, the company aims to improve outcomes for patients with hematologic diseases.
Core Business Areas
- Hematopoietic Stem Cell Transplantation Conditioning: Developing novel conditioning regimens to reduce the toxicity and improve the efficacy of stem cell transplantation.
- Gene Therapy: Developing conditioning regimens to enable safer and more effective gene therapies for genetic diseases.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure involves research and development, clinical development, and commercialization teams.
Top Products and Market Share
Key Offerings
- Busamulfan Treosulfan Combination: Jasper is developing a reduced intensity conditioning regimen using busulfan and treosulfan. Currently in clinical trials; no market share yet. Potential competitors include companies offering high-dose chemotherapy regimens and other conditioning agents.
- Anti-CD117 Antibody (JTX-101): JTX-101 is a novel anti-CD117 antibody. Currently in clinical trials; no market share yet. Potential competitors include Stemline Therapeutics, which makes ELZONRIS, an anti-CD123 targeted treatment.
Market Dynamics
Industry Overview
The hematopoietic stem cell transplantation and gene therapy fields are rapidly evolving, with increasing demand for safer and more effective conditioning regimens. The market is characterized by intense competition and regulatory scrutiny.
Positioning
Jasper Therapeutics aims to differentiate itself by developing less toxic and more targeted conditioning agents, improving patient outcomes and expanding the applicability of stem cell transplantation and gene therapy.
Total Addressable Market (TAM)
The TAM for conditioning agents in stem cell transplantation and gene therapy is estimated to be in the billions of dollars. Jasper Therapeutics is positioned to capture a significant share of this market with its novel product candidates.
Upturn SWOT Analysis
Strengths
- Novel conditioning agent technology
- Experienced management team
- Strong intellectual property position
- Focus on unmet medical needs
Weaknesses
- Early-stage clinical development
- Limited financial resources
- Dependence on clinical trial success
- Competition from established companies
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Regulatory approvals for product candidates
- Growing demand for stem cell transplantation and gene therapy
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other conditioning agents
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- BMY
- MRTX
- SGEN
- XOMA
Competitive Landscape
Jasper Therapeutics faces intense competition from established pharmaceutical companies and other biotechnology firms developing conditioning agents.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Jasper Therapeutics has experienced limited revenue growth to date, as it is focused on research and development.
Future Projections: Future growth is dependent on the successful development and commercialization of its product candidates. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing clinical trials for its conditioning agents and expanding its intellectual property portfolio.
Summary
Jasper Therapeutics is a clinical-stage biotechnology company focused on developing novel conditioning agents. The company's early-stage status presents risks, including reliance on clinical trial success and competition. The company's innovative approach offers potential for significant growth. The company needs to continue securing funding and navigating regulatory hurdles effectively to achieve long-term success. It is very early for the company.
Similar Companies
- CRIS
- AGEN
- VERU
- GRCL
- BLU
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jasper Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-01-10 | President, CEO & Director Mr. Ronald A. Martell | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://jaspertx.com |
Full time employees 64 | Website https://jaspertx.com | ||
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.